Related Experiment Video
Updated: Jun 9, 2026
09:36
Polyethyleneimine-coated Iron Oxide Nanoparticles as a Vehicle for the Delivery of Small Interfering RNA to Macrophages In Vitro and In Vivo
Published on: February 5, 2019
Overcoming RNAi transduction in leukocytes using targeted and stabilized nanoparticles
1Center for Nanoscience and Nanotechnology, George S Wise Faculty of Life Sciences, Department of Cell Research and Immunology, Laboratory of Nanomedicine, Tel Aviv University, Tel Aviv, Israel.
Idrugs : the Investigational Drugs Journal
|August 28, 2010
Summary
RNA interference (RNAi) offers therapeutic potential, but delivering RNAi molecules systemically, especially to immune cells, remains challenging. A novel nanoparticle strategy targets leukocyte integrins for specific siRNA delivery to immune cells.
Area of Science:
- Biotechnology
- Molecular Biology
- Immunology
Background:
- RNA interference (RNAi) is a powerful tool for understanding gene function in vitro and in vivo.
- RNAi holds promise as a therapeutic modality for various conditions.
- Systemic delivery of RNAi molecules, particularly to hematopoietic cells, is a significant hurdle for clinical translation.
Purpose of the Study:
- To review current systemic RNAi delivery platforms targeting leukocytes.
- To highlight the integrin-targeted stabilized nanoparticles strategy for immune cell delivery.
Main Methods:
- Review of existing literature on RNAi delivery systems.
- Focus on nanoparticle-based delivery mechanisms.
- Emphasis on targeting leukocyte integrins for selective delivery.
Main Results:
- Systemic RNAi delivery to leukocytes faces challenges.
- Integrin-targeted stabilized nanoparticles offer a promising strategy.
- This approach enables exclusive siRNA delivery to immune system cells.
Conclusions:
- Targeted delivery of RNAi to leukocytes is crucial for therapeutic applications.
- Integrin-targeted nanoparticles represent a viable platform for immune cell-specific RNAi delivery.
- This strategy could overcome current limitations in translating RNAi into clinical therapies for immune-related diseases.
